Published in EMBO Rep on July 01, 2005
Molecular analysis as an aid to assess the public health risk of non-O157 Shiga toxin-producing Escherichia coli strains. Appl Environ Microbiol (2008) 1.84
Towards pathogenomics: a web-based resource for pathogenicity islands. Nucleic Acids Res (2006) 1.24
A chemical ecogenomics approach to understand the roles of secondary metabolites in fungal cereal pathogens. Front Microbiol (2014) 0.77
Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev (2002) 17.58
Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet (2005) 16.98
The challenge of emerging and re-emerging infectious diseases. Nature (2004) 8.94
Unifying the epidemiological and evolutionary dynamics of pathogens. Science (2004) 8.33
Infectious history. Science (2000) 6.09
Diagnostics for the developing world. Nat Rev Microbiol (2004) 5.62
Infection control - a problem for patient safety. N Engl J Med (2003) 5.54
Trends in antimicrobial drug development: implications for the future. Clin Infect Dis (2004) 5.23
Ecological fitness, genomic islands and bacterial pathogenicity. A Darwinian view of the evolution of microbes. EMBO Rep (2001) 4.78
Diseases of humans and their domestic mammals: pathogen characteristics, host range and the risk of emergence. Philos Trans R Soc Lond B Biol Sci (2001) 4.68
Population biology of multihost pathogens. Science (2001) 4.39
Transmission of infectious diseases during commercial air travel. Lancet (2005) 3.97
Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis (2001) 3.68
Ecology drives the worldwide distribution of human diseases. PLoS Biol (2004) 3.57
Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci U S A (1997) 3.48
Containment of antibiotic resistance. Science (1998) 3.27
Emerging foodborne diseases. Emerg Infect Dis (1997) 3.05
Global change and human vulnerability to vector-borne diseases. Clin Microbiol Rev (2004) 2.83
Comparative quantification of health risks conceptual framework and methodological issues. Popul Health Metr (2003) 2.80
Passive antibody therapy for infectious diseases. Nat Rev Microbiol (2004) 2.64
Travel and the emergence of infectious diseases. Emerg Infect Dis (1996) 2.44
Population biology of emerging and re-emerging pathogens. Trends Microbiol (2002) 2.42
Human polymicrobial infections. Lancet (2005) 2.34
Emerging infectious diseases: a 10-year perspective from the National Institute of Allergy and Infectious Diseases. Emerg Infect Dis (2005) 2.30
Antibiotics at the crossroads. Nature (2004) 2.20
Microbial population genomics and ecology: the road ahead. Environ Microbiol (2004) 1.94
In vivo bioluminescence imaging for integrated studies of infection. Cell Microbiol (2004) 1.89
Antibiotic resistance: consequences of inaction. Clin Infect Dis (2001) 1.74
British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis (2003) 1.72
Biofilms 2003: emerging themes and challenges in studies of surface-associated microbial life. J Bacteriol (2004) 1.65
An integrated assessment framework for climate change and infectious diseases. Environ Health Perspect (1999) 1.54
Development of antimicrobial agents in the era of new and reemerging infectious diseases and increasing antibiotic resistance. JAMA (2001) 1.50
Public health response to biological and chemical weapons: WHO guidance. Biosecur Bioterror (2005) 1.50
From Pasteur to genomics: progress and challenges in infectious diseases. Nat Med (2004) 1.27
Globalization and risks to health. EMBO Rep (2004) 1.26
Emerging infectious diseases. A global fire brigade responds to disease outbreaks. Science (2004) 1.16
Bioterrorism defense priorities. Science (2003) 1.06
Response of the clinical microbiology laboratory to emerging (new) and reemerging infectious diseases. J Clin Microbiol (2004) 1.02
Genomics and bacterial pathogenesis. Emerg Infect Dis (2000) 0.98
WHO and biological weapons investigations. Lancet (2005) 0.98
Better control of antibiotic resistance. Clin Infect Dis (2001) 0.89
Vaccines as tools for advancing more than public health: perspectives of a former director of the National Vaccine Program office. Clin Infect Dis (2001) 0.87
Focusing light on infection in four dimensions. Cell Microbiol (2004) 0.84
Product R&D for neglected diseases. Twenty-seven years of WHO/TDR experiences with public-private partnerships. EMBO Rep (2003) 0.83
Antiinfective biotechs face partnering gap. Nat Biotechnol (2005) 0.78
Biological weapons, genetics, and social analysis: emerging responses, emerging issues--II. New Genet Soc (2003) 0.77
The future of stem-cell research in Germany. A Delphi study. EMBO Rep (2004) 0.99
Stem-cell research: the state of the art. Future regulations of embryonic-stem-cell research will be influenced more by economic interests and cultural history than by ethical concerns. EMBO Rep (2005) 0.79
Clone wars? EMBO Rep (2006) 0.75
Trust in the safety of tourist destinations: hard to gain, easy to lose? New insights on the asymmetry principle. Risk Anal (2008) 0.75
Uptake, transport and accumulation of nicotine by the Golden Potho (Epipremnum aureum): the central role of root pressure. J Plant Physiol (2005) 0.75